 Daniel Pastula
Concepts (219)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Zika Virus Infection | 9 | 2018 | 169 | 1.930 |
Why?
| | Encephalitis, California | 4 | 2019 | 11 | 1.690 |
Why?
| | Epilepsy | 7 | 2024 | 375 | 1.490 |
Why?
| | Guillain-Barre Syndrome | 5 | 2017 | 23 | 1.380 |
Why?
| | Encephalitis, Tick-Borne | 3 | 2023 | 8 | 1.290 |
Why?
| | Flavivirus Infections | 2 | 2019 | 9 | 1.250 |
Why?
| | Disease Outbreaks | 8 | 2023 | 430 | 1.200 |
Why?
| | Amyotrophic Lateral Sclerosis | 6 | 2015 | 102 | 1.190 |
Why?
| | Central Nervous System Diseases | 2 | 2023 | 73 | 1.170 |
Why?
| | Bunyaviridae Infections | 3 | 2019 | 15 | 1.160 |
Why?
| | Monkeypox virus | 3 | 2023 | 23 | 1.130 |
Why?
| | Sexual and Gender Minorities | 2 | 2022 | 245 | 1.120 |
Why?
| | Nervous System Diseases | 4 | 2023 | 283 | 1.020 |
Why?
| | Meningitis | 2 | 2023 | 81 | 0.920 |
Why?
| | Chikungunya Fever | 2 | 2017 | 85 | 0.910 |
Why?
| | Encephalitis | 3 | 2023 | 138 | 0.890 |
Why?
| | Medical Tourism | 1 | 2023 | 9 | 0.800 |
Why?
| | Arbovirus Infections | 2 | 2023 | 20 | 0.800 |
Why?
| | Neurology | 3 | 2024 | 113 | 0.790 |
Why?
| | Smallpox Vaccine | 1 | 2023 | 24 | 0.790 |
Why?
| | Flavivirus | 2 | 2019 | 19 | 0.770 |
Why?
| | Optic Neuritis | 1 | 2023 | 46 | 0.760 |
Why?
| | Encephalomyelitis | 1 | 2022 | 14 | 0.760 |
Why?
| | Encephalitis Virus, California | 3 | 2019 | 6 | 0.740 |
Why?
| | Phlebovirus | 3 | 2020 | 6 | 0.730 |
Why?
| | Exanthema | 1 | 2022 | 82 | 0.720 |
Why?
| | Mycobacterium abscessus | 1 | 2023 | 120 | 0.700 |
Why?
| | Creatine | 2 | 2012 | 63 | 0.690 |
Why?
| | Neuroprotective Agents | 2 | 2012 | 142 | 0.640 |
Why?
| | Acyclovir | 1 | 2020 | 96 | 0.630 |
Why?
| | Encephalomyelitis, Eastern Equine | 1 | 2019 | 5 | 0.620 |
Why?
| | Lymphohistiocytosis, Hemophagocytic | 2 | 2018 | 30 | 0.600 |
Why?
| | Mycobacterium Infections, Nontuberculous | 1 | 2023 | 367 | 0.560 |
Why?
| | Thrombocytopenia | 2 | 2017 | 211 | 0.560 |
Why?
| | Hepatitis E | 1 | 2017 | 2 | 0.510 |
Why?
| | Hepatitis E virus | 1 | 2017 | 2 | 0.510 |
Why?
| | Myelitis | 4 | 2021 | 106 | 0.510 |
Why?
| | Epidemiological Monitoring | 1 | 2017 | 70 | 0.500 |
Why?
| | Communicable Diseases, Emerging | 1 | 2016 | 39 | 0.470 |
Why?
| | Dengue | 1 | 2016 | 89 | 0.450 |
Why?
| | Ixodidae | 1 | 2014 | 7 | 0.420 |
Why?
| | Antiviral Agents | 1 | 2020 | 763 | 0.420 |
Why?
| | Humans | 51 | 2024 | 144738 | 0.410 |
Why?
| | Zika Virus | 5 | 2018 | 132 | 0.400 |
Why?
| | Enterovirus Infections | 3 | 2021 | 174 | 0.340 |
Why?
| | Critical Care | 1 | 2017 | 691 | 0.340 |
Why?
| | Homosexuality, Male | 2 | 2022 | 207 | 0.340 |
Why?
| | Meningoencephalitis | 2 | 2021 | 24 | 0.330 |
Why?
| | Fatal Outcome | 4 | 2018 | 313 | 0.270 |
Why?
| | Muscle Hypotonia | 2 | 2018 | 33 | 0.270 |
Why?
| | Male | 25 | 2024 | 72206 | 0.260 |
Why?
| | United States | 11 | 2024 | 15693 | 0.260 |
Why?
| | Infant | 9 | 2022 | 10095 | 0.260 |
Why?
| | Population Surveillance | 4 | 2018 | 493 | 0.260 |
Why?
| | North America | 2 | 2019 | 312 | 0.260 |
Why?
| | Motor Neuron Disease | 3 | 2012 | 21 | 0.250 |
Why?
| | Culicidae | 2 | 2016 | 35 | 0.230 |
Why?
| | Child, Preschool | 8 | 2022 | 11876 | 0.230 |
Why?
| | Enterovirus D, Human | 2 | 2016 | 87 | 0.220 |
Why?
| | Animals | 11 | 2023 | 38223 | 0.210 |
Why?
| | Rituximab | 2 | 2023 | 207 | 0.200 |
Why?
| | Infant, Newborn | 4 | 2022 | 6418 | 0.200 |
Why?
| | Glial Fibrillary Acidic Protein | 2 | 2023 | 112 | 0.200 |
Why?
| | Autoimmune Diseases of the Nervous System | 1 | 2023 | 30 | 0.200 |
Why?
| | Child | 10 | 2022 | 22928 | 0.200 |
Why?
| | Myelin-Oligodendrocyte Glycoprotein | 1 | 2023 | 55 | 0.190 |
Why?
| | Encephalitis, Viral | 1 | 2023 | 45 | 0.190 |
Why?
| | District of Columbia | 1 | 2022 | 34 | 0.190 |
Why?
| | Adolescent | 11 | 2024 | 22670 | 0.190 |
Why?
| | West Nile Fever | 1 | 2023 | 57 | 0.190 |
Why?
| | Middle Aged | 12 | 2024 | 35635 | 0.180 |
Why?
| | Enterovirus A, Human | 1 | 2021 | 13 | 0.170 |
Why?
| | Health Surveys | 2 | 2024 | 512 | 0.170 |
Why?
| | Age of Onset | 2 | 2015 | 559 | 0.170 |
Why?
| | Acute Disease | 4 | 2018 | 1017 | 0.170 |
Why?
| | Registries | 1 | 2009 | 2251 | 0.160 |
Why?
| | Education, Medical | 1 | 2024 | 275 | 0.160 |
Why?
| | Young Adult | 7 | 2024 | 14020 | 0.160 |
Why?
| | Vital Capacity | 2 | 2012 | 312 | 0.160 |
Why?
| | Adult | 12 | 2024 | 40355 | 0.160 |
Why?
| | Hashimoto Disease | 1 | 2020 | 11 | 0.160 |
Why?
| | Central Nervous System Viral Diseases | 1 | 2021 | 77 | 0.160 |
Why?
| | Simplexvirus | 1 | 2020 | 82 | 0.160 |
Why?
| | Colorado | 3 | 2022 | 4704 | 0.160 |
Why?
| | Interferon-gamma | 1 | 2023 | 797 | 0.160 |
Why?
| | Bunyamwera virus | 1 | 2019 | 3 | 0.160 |
Why?
| | Incidence | 5 | 2018 | 2863 | 0.150 |
Why?
| | Disease Progression | 4 | 2012 | 2889 | 0.150 |
Why?
| | Administration, Intravenous | 1 | 2020 | 172 | 0.150 |
Why?
| | Comorbidity | 1 | 2024 | 1685 | 0.150 |
Why?
| | Neuromuscular Diseases | 1 | 2021 | 144 | 0.150 |
Why?
| | Central Nervous System Infections | 1 | 2019 | 35 | 0.150 |
Why?
| | Immunologic Factors | 1 | 2021 | 253 | 0.150 |
Why?
| | Stem Cells | 1 | 2023 | 620 | 0.140 |
Why?
| | Immunoglobulin G | 1 | 2023 | 900 | 0.140 |
Why?
| | Aged | 10 | 2024 | 25562 | 0.140 |
Why?
| | Autopsy | 2 | 2015 | 98 | 0.140 |
Why?
| | Seizures | 1 | 2022 | 457 | 0.140 |
Why?
| | La Crosse virus | 1 | 2017 | 7 | 0.140 |
Why?
| | Motor Disorders | 1 | 2018 | 17 | 0.140 |
Why?
| | Veterans | 1 | 2009 | 1565 | 0.130 |
Why?
| | Skin | 1 | 2022 | 774 | 0.130 |
Why?
| | Micronesia | 1 | 2017 | 7 | 0.130 |
Why?
| | Fever | 2 | 2017 | 312 | 0.130 |
Why?
| | Encephalomyelitis, Equine | 1 | 2016 | 3 | 0.130 |
Why?
| | Encephalitis Virus, Eastern Equine | 1 | 2016 | 5 | 0.130 |
Why?
| | Magnetic Resonance Imaging | 2 | 2023 | 3834 | 0.130 |
Why?
| | Fiji | 1 | 2016 | 2 | 0.130 |
Why?
| | International Classification of Diseases | 1 | 2017 | 142 | 0.130 |
Why?
| | Pandemics | 2 | 2023 | 1677 | 0.130 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2012 | 1673 | 0.120 |
Why?
| | Diagnostic Errors | 1 | 2017 | 177 | 0.120 |
Why?
| | Arthropod Vectors | 1 | 2016 | 7 | 0.120 |
Why?
| | Neurologic Examination | 1 | 2016 | 127 | 0.120 |
Why?
| | Female | 16 | 2024 | 78069 | 0.120 |
Why?
| | Encephalitis Viruses, Tick-Borne | 1 | 2016 | 8 | 0.120 |
Why?
| | Ticks | 1 | 2016 | 29 | 0.120 |
Why?
| | Antibodies, Viral | 4 | 2023 | 668 | 0.120 |
Why?
| | Thogotovirus | 1 | 2015 | 1 | 0.120 |
Why?
| | Lyme Disease | 1 | 2015 | 58 | 0.110 |
Why?
| | Aged, 80 and over | 3 | 2017 | 8102 | 0.110 |
Why?
| | Health Services Needs and Demand | 1 | 2017 | 283 | 0.110 |
Why?
| | T-Lymphocytes | 1 | 2023 | 2042 | 0.110 |
Why?
| | Chikungunya virus | 1 | 2016 | 87 | 0.110 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2018 | 420 | 0.100 |
Why?
| | Plant Oils | 1 | 2013 | 32 | 0.100 |
Why?
| | Cluster Analysis | 1 | 2014 | 529 | 0.100 |
Why?
| | Puerto Rico | 3 | 2017 | 54 | 0.100 |
Why?
| | Linear Models | 1 | 2015 | 860 | 0.090 |
Why?
| | Age Factors | 2 | 2018 | 3336 | 0.090 |
Why?
| | Models, Statistical | 1 | 2017 | 689 | 0.090 |
Why?
| | Quality of Life | 2 | 2022 | 3100 | 0.090 |
Why?
| | Curriculum | 1 | 2019 | 1064 | 0.090 |
Why?
| | Biopsy | 1 | 2015 | 1091 | 0.090 |
Why?
| | Case-Control Studies | 2 | 2016 | 3644 | 0.090 |
Why?
| | Health Promotion | 1 | 2017 | 766 | 0.080 |
Why?
| | Emergency Service, Hospital | 1 | 2022 | 2290 | 0.080 |
Why?
| | Hospitalization | 2 | 2017 | 2342 | 0.080 |
Why?
| | Vietnam | 1 | 2009 | 29 | 0.080 |
Why?
| | Multiple Sclerosis | 1 | 2015 | 487 | 0.080 |
Why?
| | Muscle Cramp | 1 | 2009 | 7 | 0.080 |
Why?
| | Piracetam | 1 | 2009 | 13 | 0.080 |
Why?
| | Alzheimer Disease | 1 | 2015 | 617 | 0.070 |
Why?
| | Parkinson Disease | 1 | 2015 | 596 | 0.070 |
Why?
| | Muscle Spasticity | 1 | 2009 | 63 | 0.070 |
Why?
| | Dietary Supplements | 1 | 2013 | 583 | 0.070 |
Why?
| | Influenza, Human | 1 | 2015 | 637 | 0.070 |
Why?
| | Anticonvulsants | 1 | 2009 | 230 | 0.060 |
Why?
| | Kaplan-Meier Estimate | 1 | 2009 | 924 | 0.060 |
Why?
| | Proportional Hazards Models | 1 | 2009 | 1296 | 0.060 |
Why?
| | United States Department of Veterans Affairs | 1 | 2009 | 744 | 0.060 |
Why?
| | Brain | 1 | 2017 | 2909 | 0.050 |
Why?
| | Prevalence | 2 | 2024 | 2849 | 0.050 |
Why?
| | Survival Rate | 1 | 2009 | 2025 | 0.050 |
Why?
| | Clinical Trials as Topic | 1 | 2008 | 1048 | 0.050 |
Why?
| | Astrocytes | 1 | 2023 | 219 | 0.040 |
Why?
| | Eosinophils | 1 | 2023 | 325 | 0.040 |
Why?
| | Cross Reactions | 1 | 2020 | 134 | 0.040 |
Why?
| | Microspheres | 1 | 2020 | 142 | 0.040 |
Why?
| | Immunoassay | 1 | 2020 | 110 | 0.040 |
Why?
| | Antigens, Viral | 1 | 2020 | 179 | 0.040 |
Why?
| | Inpatients | 1 | 2024 | 525 | 0.040 |
Why?
| | Immunoglobulin M | 1 | 2020 | 288 | 0.040 |
Why?
| | Chronic Disease | 1 | 2024 | 1844 | 0.040 |
Why?
| | Missouri | 1 | 2018 | 60 | 0.030 |
Why?
| | Epilepsia Partialis Continua | 1 | 2017 | 3 | 0.030 |
Why?
| | B-Lymphocytes | 1 | 2023 | 886 | 0.030 |
Why?
| | Epilepsy, Generalized | 1 | 2017 | 19 | 0.030 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2020 | 196 | 0.030 |
Why?
| | Ohio | 1 | 2017 | 144 | 0.030 |
Why?
| | Paraplegia | 1 | 2017 | 61 | 0.030 |
Why?
| | Insurance, Major Medical | 1 | 2017 | 2 | 0.030 |
Why?
| | Delphi Technique | 1 | 2019 | 327 | 0.030 |
Why?
| | Communication | 1 | 2024 | 966 | 0.030 |
Why?
| | Arkansas | 1 | 2016 | 22 | 0.030 |
Why?
| | Epilepsies, Partial | 1 | 2017 | 58 | 0.030 |
Why?
| | Medical Records | 1 | 2017 | 185 | 0.030 |
Why?
| | Muscle Weakness | 1 | 2017 | 95 | 0.030 |
Why?
| | Microcephaly | 1 | 2018 | 103 | 0.030 |
Why?
| | Serologic Tests | 1 | 2016 | 54 | 0.030 |
Why?
| | Serogroup | 1 | 2016 | 46 | 0.030 |
Why?
| | Headache | 1 | 2017 | 159 | 0.030 |
Why?
| | Immunocompromised Host | 1 | 2018 | 206 | 0.030 |
Why?
| | Monte Carlo Method | 1 | 2017 | 155 | 0.030 |
Why?
| | Long-Term Care | 1 | 2017 | 115 | 0.030 |
Why?
| | Public Health Surveillance | 1 | 2016 | 83 | 0.030 |
Why?
| | Autoantibodies | 1 | 2023 | 1503 | 0.030 |
Why?
| | Spasms, Infantile | 1 | 2017 | 136 | 0.030 |
Why?
| | Geographic Mapping | 1 | 2015 | 27 | 0.030 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2016 | 130 | 0.030 |
Why?
| | Kansas | 1 | 2015 | 28 | 0.030 |
Why?
| | Self-Management | 1 | 2018 | 207 | 0.030 |
Why?
| | Forecasting | 1 | 2017 | 386 | 0.030 |
Why?
| | Electroencephalography | 1 | 2017 | 532 | 0.030 |
Why?
| | Pregnancy | 2 | 2018 | 7211 | 0.030 |
Why?
| | Vaccination | 1 | 2023 | 1489 | 0.030 |
Why?
| | Neurodegenerative Diseases | 1 | 2015 | 143 | 0.030 |
Why?
| | Coconut Oil | 1 | 2013 | 3 | 0.030 |
Why?
| | Public Health | 1 | 2018 | 567 | 0.020 |
Why?
| | Genome, Viral | 1 | 2015 | 225 | 0.020 |
Why?
| | Nutrition Therapy | 1 | 2013 | 36 | 0.020 |
Why?
| | Databases, Factual | 1 | 2017 | 1477 | 0.020 |
Why?
| | RNA, Viral | 1 | 2015 | 708 | 0.020 |
Why?
| | Clinical Competence | 1 | 2019 | 1252 | 0.020 |
Why?
| | Phylogeny | 1 | 2015 | 1015 | 0.020 |
Why?
| | Placebos | 1 | 2009 | 195 | 0.020 |
Why?
| | Review Literature as Topic | 1 | 2008 | 52 | 0.020 |
Why?
| | Treatment Outcome | 2 | 2016 | 11494 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2016 | 2798 | 0.010 |
Why?
| | Anti-Bacterial Agents | 1 | 2016 | 1916 | 0.010 |
Why?
| | Data Collection | 1 | 2008 | 657 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2018 | 6060 | 0.010 |
Why?
| | Time Factors | 1 | 2016 | 7071 | 0.010 |
Why?
| | Biomarkers | 1 | 2016 | 4276 | 0.010 |
Why?
| | Risk Factors | 1 | 2018 | 10736 | 0.010 |
Why?
| | Pilot Projects | 1 | 2009 | 1848 | 0.010 |
Why?
| | Research Design | 1 | 2008 | 1126 | 0.010 |
Why?
| | Biomedical Research | 1 | 2008 | 706 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2016 | 16940 | 0.010 |
Why?
|
|
Pastula's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|